| Chronic kidney disease (CKD) is an established independent risk factor for cardiovascular disease (CVD) and is caused by chronic pyelonephritis (CP). This study aimed to investigate the effect of the association of cardiovascular markers with the course of CP on the comorbidity of CP with ischemic heart disease. The study participants included 125 patients with CP without symptoms of urinary tract obstruction who were divided into three groups. The first group (n=45) consisted of patients with recurrent CP (CPr) three or more times per year. The second group (n=42) included patients with active phase pyelonephritis (CPa), with a frequency of two times or less per year, with concomitant pathology (stable coronary artery disease, functional class I - II), and the third group (n=38) included patients with an inactive phase of the disease (CPi), with a history of pyelonephritis of at least five years. The patients’ carotid artery augmentation index (AI %) and the change in the diameter of the brachial artery (D %) in CPi, CPa, and CPr groups were 8.44±1.76, 15.47±4.00, 11.71±1.70, 13.81±3.06, 12.75±2.55 and 6.54±3.27, respectively. The left ventricular ejection fraction (EF) index in the three study groups was estimated to be 68.92±3.76, 64.76±2.75, and 66.28±3.45%, respectively. An analysis of the results showed the most significant changes in the parameters of the cardiovascular system in patients with a comorbid and relapsing course of CP. The results showed a significant increase in pulmonary artery diameter, EF, left ventricular pressure and volume, pulse wave velocity in the aorta, and vascular resistance index. |
- Perlman RL, Finkelstein FO, Liu L, Roys E, Kiser M, Eisele G, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis. 2005;45(4):658-66.
- Ruszkowski J, Heleniak Z, Król E, Tarasewicz A, Gałgowska J, Witkowski JM, et al. Constipation and the Quality of Life in Conservatively Treated Chronic Kidney Disease Patients: A Cross-sectional Study. Int J Med Sci. 2020;17(18):2954.
- Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302-8.
- Martin H. Laboratory measurement of urine albumin and urine total protein in screening for proteinuria in chronic kidney disease. Clin Biochem Rev. 2011;32(2):97.
- Moledina DG, Luciano RL, Kukova L, Chan L, Saha A, Nadkarni G, et al. Kidney biopsy–related complications in hospitalized patients with acute kidney disease. Clin J Am Soc Nephrol. 2018;13(11):1633-40.
- Molnar MZ, Kalantar-Zadeh K, Lott EH, Lu JL, Malakauskas SM, Ma JZ, et al. Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. J Am Coll Cardiol. 2014;63(7):650-8.
- Arcari L, Engel J, Freiwald T, Zhou H, Zainal H, Gawor M, et al. Cardiac biomarkers in chronic kidney disease are independently associated with myocardial edema and diffuse fibrosis by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2021;23(1):1-14.
- Noble R, Taal MW. Epidemiology and causes of chronic kidney disease. Medicine. 2019;47(9):562-6.
- Buleu FN, Luca CT, Tudor A, Badalica-Petrescu M, Caraba A, Pah A, et al. Correlations between vascular stiffness indicators, OPG, and 25-OH vitamin D3 status in heart failure patients. Medicina. 2019;55(6):309.
- Saritas T, Floege J. Cardiovascular disease in patients with chronic kidney disease. Herz. 2020:1-7.
- Lessey G, Stavropoulos K, Papademetriou V. Mild to moderate chronic kidney disease and cardiovascular events in patients with type 2 diabetes mellitus. Vasc Health Risk Manag. 2019;15:365.
- Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders H-J. Acute kidney injury. Nat Rev Dis Primers. 2021;7(1):1-17.
- Desjardins L, Liabeuf S, Oliveira RB, Louvet L, Kamel S, Lemke H-D, et al. Uremic toxicity and sclerostin in chronic kidney disease patients. Nephrol Ther. 2014;10(6):463-70.
- Van den Broek D, Chang YM, Elliott J, Jepson R. Chronic kidney disease in cats and the risk of total hypercalcemia. J Vet Intern Med. 2017;31(2):465-75.
- Hall ME, do Carmo JM, da Silva AA, Juncos LA, Wang Z, Hall JE. Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis. 2014;7:75.
- Fuhrmann I, Krause R. Principles of exercising in patients with chronic kidney disease, on dialysis and for kidney transplant recipients. Clin Nephrol. 2004;61:S14-25.
- Moradi H, Sica DA, Kalantar-Zadeh K. Cardiovascular burden associated with uremic toxins in patients with chronic kidney disease. Am J Nephrol. 2013;38(2):136-48.
- Foster JD, Krishnan H, Cole S. Characterization of subclinical bacteriuria, bacterial cystitis, and pyelonephritis in dogs with chronic kidney disease. J Am Vet Med Assoc. 2018;252(10):1257-62.
- Kulik Y, Martymianova L, Rybchynskyi S, Kartvelishviliy HY. Chronic renal disease as a cause of cardiovascular pathology. Вестник Харьковского
национального университета имени ВН Каразина
Серия «Медицина». 2017(33).
- Chinnappa S, White E, Lewis N, Baldo O, Tu Y-K, Glorieux G, et al. Early and asymptomatic cardiac dysfunction in chronic kidney disease. Nephrol Dial Transplant. 2018;33(3):450-8.
- Kompa A, Nguyen C, Edgley A, Kelly D. P3493 Uremic toxin induced endothelial dysfunction can be restored by inhibition of the aryl hydrocarbon receptor: implications for cardiovascular disease treatment in chronic kidney disease patients. Eur Heart J. 2019;40(1):745.
- Abaturov AY, Vakulenko LI, Kunak OV. Correlation between endothelial dysfunction and left ventricular hypertrophy in children with initial stages chronic kidney disease. HVM Bioflux. 2019;11(3):126-30.
- Hulshoff MS, Rath SK, Xu X, Zeisberg M, Zeisberg EM, editors. Causal connections from chronic kidney disease to cardiac fibrosis. Seminars in nephrology; 2018: Elsevier.
|
